Clinical trials: Esophagogastric Junction Disorder
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M05D1 in patients with Claudin (CLDN) 18.2-positive advanced gastric cancer or gastroesophageal…
- Trial name
- NCT07518147
- Testing
- BL-M05D1, Paclitaxel, Docetaxel
- Where
- China
- Volunteers
- 438 people
- Sponsor
- Biokin (Shanghai) Biopharmaceutical Co., Ltd.
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
ctDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPR
This prospective observational study will enroll adults with gastric or gastroesophageal junction adenocarcinoma who achieve pathological complete response or major pathological response after neoadjuvant therapy and R0…
- Trial name
- NCT07799649
- Testing
- Tumor-Informed ctDNA-MRD Monitoring, Clinician-Selected Standard-of-Care Postoperative Treatment
- Where
- China
- Volunteers
- 150 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Lung Cancer Metastatic, Renal Cell Carcinoma
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers.
- Conditions
- Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer
- Trial name
- MOIO (NCT05078047)
- Testing
- Reduced dose intensity of IO
- Where
- 33 sites in France
- Volunteers
- 646 people
- Sponsor
- UNICANCER
Gastric Cancer
A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma
This is a Phase III randomized multicenter double-blind, placebo controlled trial evaluating the safety and efficacy of paclitaxel plus ramucirumab (IMC-1211B) drug product (DP) compared to paclitaxel plus placebo.
- Trial name
- RAINBOW (NCT01170663)
- Testing
- Ramucirumab (IMC-1211B) DP, Paclitaxel
- Where
- 167 sites in United States, Argentina and 24 more
- Volunteers
- 665 people
- Sponsor
- Eli Lilly and Company
Gastric Adenocarcinoma, Esophagus Adenocarcinoma
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5-fluorouracile (5-FU) in frail patients with advanced, recurrent or metastatic gastric, oesophageal or gastroesophageal junction cancer.
- Conditions
- Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- LOGICAN (NCT05476796)
- Testing
- Trifluridine/Tipiracil, Oxaliplatin, FOLFOX regimen
- Where
- 28 sites in France
- Volunteers
- 118 people
- Sponsor
- UNICANCER
Advanced Gastric Cancer, Esophagogastric Junction Cancer
A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy
Adult patients with gastric carcinoma which has progressed after initial treatment with a fluoropyrimidines-containing regimen will be treated with paclitaxel plus RAD001 or plus placebo.
- Trial name
- AIO-STO-0111 (NCT01248403)
- Testing
- Paclitaxel, RAD001
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Krankenhaus Nordwest
Gastric Cancer Stage III
Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial
The goal of this clinical trial is to learn if Omega-3 fatty acids supplementation can enhance the efficacy of neoadjuvant immunotherapy in patients with locally advanced gastric and gastroesophageal junction adenocarcinoma.
- Trial name
- NCT07050524
- Testing
- Omega-3 Supplementation, Neoadjuvant Immunotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma
Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma
The purpose of this clinical trial is to evaluate whether perioperative fruquintinib combined with sintilimab and SOX is effective in treating locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Trial name
- NCT07658872
- Testing
- fruquintinib + sintilimab + SOX, Sinitilimab+SOX
- Volunteers
- 120 people
- Sponsor
- Sichuan University
Carcinoma, Non-Small-Cell Lung, Gastric Cancer
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced solid tumors.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
- Trial name
- NCT04931654
- Testing
- AZD7789
- Where
- 21 sites in United States, Canada and 8 more
- Volunteers
- 136 people
- Sponsor
- AstraZeneca
Esophageal Cancer
Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Drugs used in chemotherapy such as paclitaxel, fluorouracil, and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00069953
- Testing
- filgrastim, pegfilgrastim, cisplatin
- Where
- 97 sites in United States
- Volunteers
- 43 people
- Sponsor
- Radiation Therapy Oncology Group
Solid Tumor, Colorectal Cancer
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
This is a first-in-human Phase 1a/1b, multicenter, open-label, dose-escalation, dose and schedule optimization, and expansion study of TPST-1495 as a single agent and in combination with pembrolizumab to determine its maximum…
- Conditions
- Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04344795
- Testing
- TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 89 people
- Sponsor
- Tempest Therapeutics
Gastric/Gastroesophageal Junction Adenocarcinoma
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
To evaluate the initial efficacy and safety of paclitaxel for injection (albumin-bound) in combination with apatinib mesylate and adebrelimab in the treatment of locally advanced or metastatic gastric/gastroesophageal junction…
- Trial name
- NCT06415669
- Testing
- Paclitaxel for injection (albumin-bound), Adebrelimab, Apatinib mesylate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Gastroesophageal Reflux Disease
Antireflux Ablation Therapy (ARAT) Vs Antireflux Mucosectomy (ARMS) In The Management Of Gastroesophageal Reflux Disease
Gastroesophageal reflux disease has a high global prevalence, proton pump inhibitors are the cornerstone in the management but 10-20% of the patients are refractory to these, surgical treatment being an option of treatment in…
- Trial name
- NCT04036942
- Testing
- Ablation of the gastroesophageal junction with hybrid argon plasma, mucosectomy with band of the gastroesophageal junction
- Where
- Mexico
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Neoplasms, Gastrointestinal Tract
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
This was an international multi-center trial that enrolled patients with locally advanced, unresectable, or metastatic gastric, esophageal, or gastro-esophageal junction cancer whose tumors had amplification of the ErbB2 (HER2)…
- Trial name
- NCT00680901
- Testing
- Lapatinib, Capecitabine, Oxaliplatin
- Where
- 183 sites in United States, Argentina and 21 more
- Volunteers
- 545 people
- Sponsor
- Novartis Pharmaceuticals
Gastric Cancer
Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD)and safety of Apatinib combined with S-1 as Second-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma.
- Trial name
- NCT03276156
- Testing
- Apatinib plus S-1
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Zhejiang Cancer Hospital
Cancer of the Head and Neck, Cancer of the Lung
Incidence and Patterns of Nausea/Vomiting With Combined Chemotherapy and Radiation
Questionnaire study to observe the incidence and pattern or nausea and vomiting in patients receiving combined chemotherapy and radiation.
- Conditions
- Cancer of the Head and Neck, Cancer of the Lung, Cancer of the Esophagus, Gastro-esophageal Junction Cancer
- Trial name
- NCT00716157
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Thomas Jefferson University
Stomach Cancer, Esophageal Cancer
A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer
The purpose of this study is to determine whether ramucirumab when used in conjunction with chemotherapy treatment can help participants with stomach, esophagus, and gastroesophageal cancer.
- Trial name
- NCT01246960
- Testing
- Ramucirumab, Oxaliplatin, Leucovorin
- Where
- 58 sites in United States
- Volunteers
- 168 people
- Sponsor
- Eli Lilly and Company
Gastric Cancer (Diagnosis), Gastric Cancer (GC)
A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma
This study is a domestic, multicenter, single-arm clinical trial designed to evaluate the efficacy and safety of heterogeneous radiotherapy (high and low dose) sequenced with iparomlimab and tuvonralimab plus SOX as a first-line…
- Conditions
- Gastric Cancer (Diagnosis), Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT07502027
- Testing
- Iparomlimab and Tuvonralimab (QL1706)
- Volunteers
- 55 people
- Sponsor
- Huazhong University of Science and Technology
Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
This phase II trial studies how well pembrolizumab and palliative radiation therapy works in treating patients with esophagus, stomach, or gastroesophageal junction cancer that has spread to other parts of the body.
- Conditions
- Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Stomach
- Trial name
- NCT02830594
- Testing
- External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- City of Hope Medical Center
Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction
Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG
IMAGINE is a Phase II, randomized, two-arm, chemotherapy controlled modular trial in subjects with histologically confirmed, resectable gastric cancer (GC) or adenocarcinoma of the gastroesophageal junction (AEG).
- Trial name
- IMAGINE (NCT04062656)
- Testing
- Nivolumab, relatlimab, Oxaliplatin
- Where
- 3 sites in Germany
- Volunteers
- 21 people
- Sponsor
- University Hospital, Essen